secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2023-01-25T23:59:59+00:00
Accession:  0001213900-23-005108
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 3.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal Therapeutics completes $7M IPO at $5/share and receives FDA Fast Track for tecarfarin
--------------------------------------------------------------------------------

- IPO of 1.4M shares at $5.00 closed Jan 24, raising $7.0M gross; stock trades on Nasdaq as CVKD.
- FDA granted Fast Track designation for tecarfarin in ESRD and atrial fibrillation patients.
- Appointed directors: Glynn Wilson (Class I), John Murphy (Class II), Steven Zelenkofske (Class III).
- Employment agreements: CFO Szot ($375K salary, 50% target bonus); CMO Losordo ($425K, 40% bonus).
- Issued 600K shares to HESP LLC, 1.14M on note conversion, 250K on warrant exercise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390023005108/0001213900-23-005108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390023005108/ea172140-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-005108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer